-

Travere Therapeutics to Present at the Guggenheim Emerging Outlook Biotech Summit

SAN DIEGO--(BUSINESS WIRE)--Travere Therapeutics, Inc. (NASDAQ: TVTX) today announced that company management will present at the Guggenheim Emerging Outlook: Biotech Summit 2026 on Wednesday, February 11, 2026, at 4:00 p.m. ET.

Travere Therapeutics will present at the Guggenheim Emerging Outlook: Biotech Summit 2026 on Wednesday, February 11, 2026, at 4:00 p.m. ET.

Share

A live webcast will be accessible on the Investor page of Travere’s website at ir.travere.com/events-and-presentations, and a replay will be available for up to 30 days following the event.

About Travere Therapeutics

At Travere Therapeutics, we are in rare for life. We are a biopharmaceutical company that comes together every day to help patients, families, and caregivers of all backgrounds as they navigate life with a rare disease. On this path, we know the need for treatment options is urgent – that is why our global team works with the rare disease community to identify, develop, and deliver life-changing therapies. In pursuit of this mission, we continuously seek to understand the diverse perspectives of rare patients and to courageously forge new paths to make a difference in their lives and provide hope – today and tomorrow. For more information, visit travere.com.

Contacts

Investors:
888-969-7879
IR@travere.com

Media:
888-969-7879
mediarelations@travere.com

Travere Therapeutics, Inc.

NASDAQ:TVTX
Details
Headquarters: San Diego, CA
CEO: Eric Dube, Ph.D.
Employees: 385
Organization: PUB

Release Versions

Contacts

Investors:
888-969-7879
IR@travere.com

Media:
888-969-7879
mediarelations@travere.com

Social Media Profiles
More News From Travere Therapeutics, Inc.

Travere Therapeutics to Report Third Quarter 2026 Financial Results

SAN DIEGO--(BUSINESS WIRE)--Travere Therapeutics, Inc. (Nasdaq: TVTX) today announced it will report third quarter 2026 financial results on Monday, November 2, 2026, after the close of the U.S. financial markets. The Company will host a conference call and webcast to discuss the financial results and provide a general business update at 4:30 p.m. ET.The webcast and dial-in information can be accessed on the Investor page of Travere’s website at https://ir.travere.com/events-and-presentations. F...

Travere Presents New Biomarker Data at ASN Kidney Week Suggesting FILSPARI® (sparsentan) May Modify Underlying Disease Pathophysiology in IgA Nephropathy

SAN DIEGO--(BUSINESS WIRE)--Travere Therapeutics, Inc. (Nasdaq: TVTX) today presented new biomarker data from the Phase 3 PROTECT Study providing evidence that FILSPARI® (sparsentan) may modify the underlying disease pathophysiology in people with IgA nephropathy (IgAN). Data were shared today in an oral presentation at the American Society of Nephrology (ASN) Kidney Week 2026 in Denver, CO.“These biomarker data provide new insight into how FILSPARI’s dual mechanism of action may modify the unde...

Travere Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

SAN DIEGO--(BUSINESS WIRE)--Travere Therapeutics, Inc. (Nasdaq: TVTX) today announced that on October 10, 2026, the Compensation Committee of its Board of Directors granted inducement equity grants covering an aggregate of 178,580 shares of its common stock to 33 new employees, consisting of inducement stock options to purchase an aggregate of 36,000 shares of common stock and inducement restricted stock units, or RSUs, covering an aggregate of 142,580 shares of its common stock. These induceme...
Back to Newsroom